China-based WuXi XDC Cayman Inc. (WuXi XDC), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specialising in antibody-drug conjugates (ADCs) and other bioconjugates, has announced a strategic collaboration with Earendil Labs on WuXi XDC's proprietary WuXiTecan-2 payload-linker technology platform.
Earendil Labs is an AI-powered biotech company focused on researching and developing next-generation innovative biologics for the treatment of autoimmune diseases, cancer, and other conditions with unmet medical needs.
This collaboration marks the establishment of a robust strategic partnership aimed at accelerating the development of next-generation ADCs by synergistically combining WuXi XDC's globally leading ADC technology platform with Earendil Labs' cutting-edge AI-driven antibody discovery and development capabilities to address significant unmet medical needs.
Under the agreement, WuXi XDC will grant Earendil Labs an exclusive global license to its proprietary WuXiTecan-2 payload-linker technology for use against multiple specific targets. Earendil Labs will utilise this technology to conjugate antibodies and bispecific antibodies discovered through its AI platform and to advance the development of the ADC candidates against these specific targets.
The total potential deal value could reach up to approximately $885 million, comprising an upfront payment, and certain development, regulatory, and sales milestone payments. Additionally, WuXi XDC will be eligible to receive tiered royalties on net sales upon commercialization of any resulting ADC products.
